Douglas Evan Godshall Shockwave Medical, Inc. (SWAV) insider trading activity

Douglas Evan Godshall is President & CEO of Shockwave Medical, Inc.. Currently has a direct ownership of 0 shares of SWAV, which is worth approximately $0. The most recent transaction as insider was on May 03, 2023, when has been sold 610 shares (Common Stock) at a price of $280.76 per share, resulting in proceeds of $171,263. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

100.0% 12M change

Total Value Held $0

Douglas Evan Godshall Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 03 2023	SELL Payment of exercise price or tax liability	$171,263 $280.76 p/Share	610 Reduced 0.43%	142,263 Common Stock
Apr 25 2023	SELL Payment of exercise price or tax liability	$523,058 $280.01 p/Share	1,868 Reduced 1.29%	142,873 Common Stock
Feb 21 2023	SELL Payment of exercise price or tax liability	$1,939,022 $192.88 p/Share	10,053 Reduced 6.49%	144,741 Common Stock
Feb 21 2023	SELL Open market or private sale	$5,653,200 $188.44 p/Share	30,000 Reduced 20.73%	114,741 Common Stock
Feb 21 2023	BUY Exercise of conversion of derivative security	$102,600 $3.42 p/Share	30,000 Added 17.17%	144,741 Common Stock
Feb 02 2023	SELL Payment of exercise price or tax liability	$1,597,574 $188.26 p/Share	8,486 Reduced 5.2%	154,794 Common Stock
Feb 01 2023	BUY Grant, award, or other acquisition	-	20,354 Added 11.08%	163,280 Common Stock
Nov 14 2022	SELL Open market or private sale	$7,218,600 $240.62 p/Share	30,000 Reduced 26.57%	82,926 Common Stock
Aug 11 2022	SELL Open market or private sale	$8,445,600 $281.52 p/Share	30,000 Reduced 20.99%	112,926 Common Stock
Jun 06 2022	SELL Open market or private sale	$1,322,380 $178.7 p/Share	7,400 Reduced 4.92%	142,926 Common Stock
Jun 06 2022	BUY Exercise of conversion of derivative security	$25,308 $3.42 p/Share	7,400 Added 4.69%	150,326 Common Stock
May 27 2022	SELL Open market or private sale	$455,156 $175.06 p/Share	2,600 Reduced 1.79%	142,926 Common Stock
May 27 2022	BUY Exercise of conversion of derivative security	$8,892 $3.42 p/Share	2,600 Added 1.76%	145,526 Common Stock
May 13 2022	SELL Open market or private sale	$750,000 $150.0 p/Share	5,000 Reduced 3.38%	142,926 Common Stock
May 13 2022	BUY Exercise of conversion of derivative security	$17,100 $3.42 p/Share	5,000 Added 3.27%	147,926 Common Stock
May 11 2022	SELL Open market or private sale	$2,118,750 $141.25 p/Share	15,000 Reduced 9.5%	142,926 Common Stock
May 11 2022	BUY Exercise of conversion of derivative security	$51,300 $3.42 p/Share	15,000 Added 8.67%	157,926 Common Stock
Apr 25 2022	SELL Payment of exercise price or tax liability	$334,659 $177.35 p/Share	1,887 Reduced 1.3%	142,926 Common Stock
Feb 22 2022	SELL Payment of exercise price or tax liability	$1,428,946 $158.86 p/Share	8,995 Reduced 5.85%	144,813 Common Stock
Feb 14 2022	SELL Payment of exercise price or tax liability	$748,747 $146.04 p/Share	5,127 Reduced 3.23%	153,808 Common Stock
Feb 01 2022	SELL Payment of exercise price or tax liability	$748,950 $155.03 p/Share	4,831 Reduced 3.53%	132,025 Common Stock
Feb 01 2022	BUY Grant, award, or other acquisition	-	22,079 Added 12.53%	154,104 Common Stock
Nov 18 2021	SELL Open market or private sale	$9,363,150 $208.07 p/Share	45,000 Reduced 24.74%	136,856 Common Stock
Nov 18 2021	BUY Exercise of conversion of derivative security	$153,900 $3.42 p/Share	45,000 Added 19.84%	181,856 Common Stock
Aug 18 2021	SELL Open market or private sale	$8,447,850 $187.73 p/Share	45,000 Reduced 24.74%	136,856 Common Stock

Also insider at

EYPT

EyePoint Pharmaceuticals, Inc. Healthcare

DEG